Reports Q3 revenue $3.27M, two estimates $3.55M. “We are successfully expanding relationships with eyecare specialists with product sales from our physician dispensed channel growing 36% over the prior year and increasing in each consecutive quarter so far in 2023. Our multiple sales channels for Avenova have a tremendous impact on one another, with our physician dispensed channel creating a halo effect over our over-the-counter products. When patients first learn about Avenova from their doctor, there is an inherent trust in the brand that we can leverage in our direct-to-consumer sales channel,” said Justin Hall, NovaBay CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBY: